Public Sector Pension Investment Board Sells 7,500 Shares of Inari Medical, Inc. (NASDAQ:NARI)

Public Sector Pension Investment Board trimmed its position in Inari Medical, Inc. (NASDAQ:NARI) by 6.6% in the third quarter, according to its most recent filing with the SEC. The institutional investor owned 106,364 shares of the company’s stock after selling 7,500 shares during the period. Public Sector Pension Investment Board owned about 0.18% of Inari Medical worth $4,386,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. GAMMA Investing LLC grew its holdings in shares of Inari Medical by 164.7% in the second quarter. GAMMA Investing LLC now owns 704 shares of the company’s stock valued at $34,000 after acquiring an additional 438 shares in the last quarter. Nisa Investment Advisors LLC boosted its position in Inari Medical by 83.5% in the second quarter. Nisa Investment Advisors LLC now owns 956 shares of the company’s stock worth $46,000 after purchasing an additional 435 shares during the last quarter. KBC Group NV grew its stake in Inari Medical by 39.0% in the 3rd quarter. KBC Group NV now owns 1,774 shares of the company’s stock valued at $73,000 after purchasing an additional 498 shares during the period. Benjamin F. Edwards & Company Inc. increased its position in shares of Inari Medical by 39.4% during the 2nd quarter. Benjamin F. Edwards & Company Inc. now owns 1,847 shares of the company’s stock valued at $89,000 after purchasing an additional 522 shares during the last quarter. Finally, Point72 Asia Singapore Pte. Ltd. bought a new stake in shares of Inari Medical during the 2nd quarter worth $104,000. Hedge funds and other institutional investors own 90.98% of the company’s stock.

Analyst Ratings Changes

Several equities analysts recently weighed in on the stock. Truist Financial increased their price target on shares of Inari Medical from $46.00 to $50.00 and gave the company a “hold” rating in a research report on Tuesday, October 29th. Canaccord Genuity Group raised their price target on shares of Inari Medical from $71.00 to $74.00 and gave the stock a “buy” rating in a research note on Tuesday, October 29th. Deutsche Bank Aktiengesellschaft assumed coverage on Inari Medical in a research note on Friday, August 9th. They issued a “buy” rating and a $68.00 price objective on the stock. Needham & Company LLC reissued a “hold” rating on shares of Inari Medical in a research report on Tuesday, October 29th. Finally, Robert W. Baird boosted their target price on Inari Medical from $66.00 to $67.00 and gave the company an “outperform” rating in a research note on Tuesday, October 29th. Six analysts have rated the stock with a hold rating and five have given a buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Hold” and an average price target of $58.89.

Inari Medical Stock Performance

NASDAQ:NARI opened at $52.12 on Tuesday. The business’s fifty day moving average is $46.48 and its 200 day moving average is $47.58. The firm has a market cap of $3.05 billion, a price-to-earnings ratio of -38.61 and a beta of 0.96. Inari Medical, Inc. has a 52-week low of $36.73 and a 52-week high of $67.13.

Insider Buying and Selling at Inari Medical

In other Inari Medical news, Director William Hoffman sold 60,000 shares of the firm’s stock in a transaction on Monday, November 18th. The shares were sold at an average price of $51.16, for a total value of $3,069,600.00. Following the completion of the transaction, the director now directly owns 501,233 shares of the company’s stock, valued at $25,643,080.28. This trade represents a 10.69 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CFO Mitch C. Hill sold 3,000 shares of the company’s stock in a transaction on Thursday, September 12th. The stock was sold at an average price of $45.13, for a total transaction of $135,390.00. Following the completion of the transaction, the chief financial officer now directly owns 179,600 shares in the company, valued at approximately $8,105,348. The trade was a 1.64 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 186,000 shares of company stock valued at $8,990,990 in the last quarter. 10.60% of the stock is currently owned by corporate insiders.

Inari Medical Company Profile

Inari Medical, Inc builds minimally invasive, novel, and catheter-based mechanical thrombectomy devices and accessories for the specific disease states in the United States. The company provides ClotTriever system, which is designed to core, capture, and remove large clots from large vessels for treatment of deep vein thrombosis and peripheral thrombus; FlowTriever system, a large bore catheter-based aspiration and mechanical thrombectomy system to remove large clots from large vessels in the peripheral vasculature for treating pulmonary embolism and other complex venous thromboembolism cases; InThrill system to treat small vessel thrombosis; and LimFlow system for patients who have chronic limb-threatening ischemia with no suitable endovascular or surgical revascularization options and risk of major amputation.